Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,707 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,707 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Enrollment posture brief
Registry condition breast-cancer
OPEN 423 | RECR 34% | LATE 120 | EARLY 491 | RANK #1 | SPON 98
Volume-matched condition peers
Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)
Breast Cancer lists 423 open slots (34% of 1,251 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 14 of 26
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
Wake Forest University Health Sciences
NCT02942355
Efficacy and Safety of 500mg of Fulvestrant
Beth Israel Deaconess Medical Center
NCT00585507
Evaluation of Improved Onboard Patient Imaging
Varian, a Siemens Healthineers Company
NCT06187103
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer
City of Hope Medical Center
NCT00609791
Durvalumab with Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
The Methodist Hospital Research Institute
NCT03820141
MRI-Based Preoperative Accelerated Partial Breast Irradiation
Medical College of Wisconsin
NCT02728076
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Pfizer
NCT05548127
Breast Cancer Survivors RESET (Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools): A Pilot, Feasibility Study
H. Lee Moffitt Cancer Center and Research Institute
NCT07101861
4:3 Intermittent Fasting Intervention in Adults With Breast Cancer and Overweight or Obesity
University of Colorado, Denver
NCT06399276
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
M.D. Anderson Cancer Center
NCT00929214
Integrated Actionable Aging Assessment for Cancer Patients Pilot
University of Colorado, Denver
NCT05871008
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Stephen Shiao
NCT05491226
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Pfizer
NCT05226871
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT03377387
Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT04180579
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03573648
Researching the Effect of Exercise on Cancer
Memorial Sloan Kettering Cancer Center
NCT04589468
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
Polly A. Niravath, MD
NCT01984138
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
Milton S. Hershey Medical Center
NCT06384417
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
Massachusetts General Hospital
NCT04837209
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03387553
Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT03289195
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
Providence Health & Services
NCT03650894
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT03083288
CARE (Chemotherapy Alopecia REduction)
George Washington University
NCT07201389
A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy
Massachusetts General Hospital
NCT03822312
[18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer
University of Pennsylvania
NCT02284919
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Dana-Farber Cancer Institute
NCT03789110
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
University of Chicago
NCT02788981
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
NCT03742245
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
Abramson Cancer Center at Penn Medicine
NCT04454528
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
Washington University School of Medicine
NCT02204098
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
NCT05675579
Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors
New Mexico Cancer Research Alliance
NCT06260332
Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer
Mothaffar Rimawi
NCT02547987
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
NCT05826964
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery
SURGE Therapeutics
NCT06300411
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
City of Hope Medical Center
NCT03696030
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Georgetown University
NCT03964532
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
Memorial Sloan Kettering Cancer Center
NCT05036252
Abbreviated MBCT for Depression in Older African American/Black Breast Cancer Survivors
Case Comprehensive Cancer Center
NCT06336538
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT05203445
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer
Massachusetts General Hospital
NCT02826434
A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction
Memorial Sloan Kettering Cancer Center
NCT05806138
Study Assessing QBS72S For Treating Brain Metastases
Stanford University
NCT05305365
Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
University of Miami
NCT01208974
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
NCT02293954
Determining Molecular Drivers of Radiation Dermatitis
Mayo Clinic
NCT04764682
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
Pfizer
NCT05573555
Evaluating a Physical Activity Index for Assessment and Counseling for Breast and Colon Cancer Survivors
Wake Forest University Health Sciences
NCT06340503
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Cancer page
1,251 registered trials, 423 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 423 Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer condition card totals 1,251 registered trials; most-linked intervention Fulvestrant; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.